glp-1 drugs thyroid cancer agonist like Ozempic do not increase risk GLP-1 and Family History of
Description
Question: How have manufacturers of brand-name glucagon-like peptide-1 (GLP-1) receptor agonists used the patent and regulatory system to extend periods of market exclusivity
FDA-approved for chronic weight management
But based on the public information reviewed, I would call Polly midlife-relevant , not clearly menopause-specific yet
Soon, liraglutide was approved for both T2DM (Victoza, Novo Nordisk, Denmark) and obesity under the name of Saxenda (Novo Nordisk) for once-daily use [18,20]
